

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

**CLARIFICATION ANNOUNCEMENT  
AND  
RESUMPTION OF TRADING IN SHARES**

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “Company” or “GYBYS”) noticed that there were media reports entitled “Doubling Plan proposed by GYBYS (廣藥白雲山提出「倍增計劃」)” published on the internet in the evening on 30 November 2015 regarding the relevant information on the future income plans of GYBYS.

**I. THE REPORTS APPEARED IN THE MEDIA**

The reports appeared in the media have mentioned, among other things: “During the 13th five years plan, GYBYS implements the “123 Strategy” i.e. “Doubling Plan” being the target, endeavours to develop GYBYS as a pharmaceutical enterprise with sale of 100 billion, market capitalization of 100 billion and tax amounts of 10 billion and achieved the sale target of over 150 billion by 2020”, “the deputy general manager of GYBYS disclosed that during the 12th five years plan the revenue of Guangzhou Pharmaceutical Group from sale had increased from RMB27.6 billion in 2010 to RMB64.6 billion in 2014 with a compound annual growth rate above 23%, being the period in which the fastest growth was experienced. It is estimated that the revenue of Guangzhou Pharmaceutical Group from sale will reach RMB75 billion” in 2015.

**II. CLARIFICATION**

After investigation, the Company responded to the reports appeared in the media referred to above as follows:

1. The controlling shareholder of the Company, namely Guangzhou Pharmaceutical Holdings Limited (廣州醫葯集團有限公司) (“GPHL”) convened a seminar at 15:00 on 30 November 2015 at Xiamen named “Seminar on the Strategic Cooperation of GYBYS for the 13th five years plan 2015”, the theme of the seminar being “100 billion Guang Yao and Healthy China”. At 17:30, the agreement on exploring deep business cooperation was entered into with Ali Health Technology (Beijing) Company Limited (阿里健康科

技(北京)有限公司)。At the seminar, Mr. Wang Wenchu, the deputy general manager of the Company introduced the contents of the development plan of GPLH for the 13th five years plan. After the completion of the major assets reorganization of the Company in 2013, the core business of GPLH had been integrated into the business of the Company. Reference to GYBYS at the seminar has not strictly distinguished GPLH or the Company.

2. References to estimated revenue from sale reaching RMB75 billion in 2015, “Doubling Plan” being the target, endeavours to achieve the sale target of RMB100 billion by 2017 and achieved the sale target of more than RMB150 billion by 2020 and the revenue and sale amounts involved in these references is the sum of the sales income of all subsidiaries of GPLH (including joint ventures and associates). Reference to the plan of market capitalization of 100 billion related to the Company.
3. The operating income as disclosed in the annual report of the Company is calculated according to accounting standards, which is different from the total revenue from sale as mentioned in the media. Information on revenue from sale and expectation on income must refer to the announcement(s) of the Company.

### **III. IMPORTANT NOTICE**

The Company hereby reminds its shareholders and investors that the Company’s designated media for publication of its information includes Shanghai Securities News, Securities Times, China Securities Journal, Securities Daily, the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Shareholders and investors are advised to pay attention to the investment risks.

### **IV. RESUMPTION OF TRADING IN H SHARES**

At the request of the Company, trading in H shares of the Company on the Stock Exchange was halted with effect from 9:00 a.m. on 1 December 2015 pending the release of this announcement. An application has been made by the Company to the Stock Exchange for the resumption of trading in the H shares of the Company on the Stock Exchange with effect from 9:00 a.m. on 2 December 2015.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 1 December 2015

*As at the date of this announcement, the board of directors comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Chu Xiaoping and Mr. Jiang Wenqi as independent non-executive directors.*